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Abstract
Objective:  To  evaluate  the  safety,  tolerability  and  potential  therapeutic  effects  of  gastrin-
releasing peptide  in  three  children  with  autistic  spectrum  disorder.
Methods:  Case  series  study  with  the  intravenous  administration  of  gastrin-releasing  peptide  in
the dose  of  160  pmol/kg  for  four  consecutive  days.  To  evaluate  the  results,  parental  impressions
the Childhood  Autism  Rating  Scale  (CARS)  and  the  Clinical  Global  Impression  (CGI)  Scale.  Each
child underwent  a  new  peptide  cycle  after  two  weeks.  The  children  were  followed  for  four
weeks after  the  end  of  the  infusions.
Results:  The  gastrin-releasing  peptide  was  well  tolerated  and  no  child  had  adverse  effects.
Two children  had  improved  social  interaction,  with  a  slight  improvement  in  joint  attention  and
the interaction  initiatives.  Two  showed  reduction  of  stereotypes  and  improvement  in  verbal
language. One  child  lost  his  compulsion  to  bathe,  an  effect  that  lasted  two  weeks  after  each
infusion cycle.  Average  reduction  in  CARS  score  was  2.8  points.  CGI  was  ‘‘minimally  better’’  in
two children  and  ‘‘much  better’’  in  one.
 Please cite this article as: Becker MM, Bosa C, Oliveira-Freitas VL, Goldim JR, Ohlweiler L, Roesler R, et al. Improvement of autism
pectrum disorder symptoms in three children by using gastrin-releasing peptide. J Pediatr (Rio J). 2016;92:302--6.
 Study linked to the Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
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Conclusions:  This  study  suggests  that  the  gastrin-releasing  peptide  is  safe  and  may  be  effective
in improving  key  symptoms  of  autism  spectrum  disorder,  but  its  results  should  be  inter-
preted with  caution.  Controlled  clinical  trials--randomized,  double-blinded,  and  with  more
children--are  needed  to  better  evaluate  the  possible  therapeutic  effects  of  gastrin-releasing
peptide in  autism.
©  2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Melhoria  nos  sistemas  do  transtorno  do  espectro  autista  em  três  crianc¸as,  utilizando
peptídeo  liberador  de  gastrina
Resumo
Objetivo:  Avaliar  a  seguranc¸a,  tolerabilidade  e  possíveis  efeitos  terapêuticos  do  peptídeo  li-
berador de  gastrina  em  três  crianc¸as  com  transtorno  do  espectro  autista.
Métodos:  Estudo  de  casuística  com  administrac¸ão  intravenosa  de  peptídeo  liberador  de  gastrina
na dose  de  160  pmol/kg  por  quatro  dias  consecutivos.  Para  avaliar  os  resultados,  foram  utilizadas
a impressão  dos  pais,  a  Escala  de  Classiﬁcac¸ão  de  Autismo  na  Infância  (CARS)  e  a  Escala  de
Impressão  Clínica  Global  (CGI).  Cada  crianc¸a  foi  submetida  a  novo  ciclo  de  peptídeo  após  duas
semanas. As  crianc¸as  foram  acompanhadas  por  quatro  semanas  após  o  término  das  infusões.
Resultados:  O  peptídeo  liberador  de  gastrina  foi  bem  tolerado  e  nenhuma  crianc¸a  apresentou
efeitos adversos.  Duas  crianc¸as  apresentaram  melhora  na  interac¸ão  social,  com  melhora  na
atenc¸ão compartilhada  e  nas  iniciativas  de  interac¸ão.  Duas  mostraram  reduc¸ão  dos  estereotipias
e melhora  na  linguagem  verbal.  Uma  crianc¸a  perdeu  sua  compulsão  por  banhos,  efeito  que  durou
duas semanas  após  cada  ciclo  de  infusão.  A  reduc¸ão  média  no  escore  da  CARS  foi  2,8  pontos.
Quanto à  CGI,  os  resultados  foram  ‘‘minimamente  melhor  em  duas  crianc¸as’’  e  ‘‘muito  melhor’’
em uma.
Conclusões:  Este  estudo  sugere  que  o  peptídeo  liberador  de  gastrina  é  seguro  e  pode  ser  efetivo
na melhora  dos  principais  sintomas  do  transtorno  do  espectro  autista,  porém  seus  resultados
devem ser  interpretados  com  cautela.  Ensaios  clínicos  controlados,  randomizados,  duplo-cego
e com  maior  número  de  crianc¸as  são  necessários  para  melhor  avaliar  os  possíveis  efeitos  te-
rapêuticos  do  peptídeo  liberador  de  gastrina  sobre  o  autismo.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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Autism  is  a  pervasive  development  disorder  characterized
by  severe  impairment  in  reciprocal  socialization,  qualita-
tive  problems  in  communication,  and  repetitive  or  unusual
behavior.1 The  current  estimated  prevalence  of  autism  is  one
in  every  66  children.2 Diagnosis  is  clinical  and  to  date  there  is
no  speciﬁc  treatment.3 Neurochemical,  neuropathological,
neuroimaging,  and  genetic  studies  suggests  disorganization
of  cortical  neurons  and  cerebral  disconnectivity,  determined
by  both  genetic  and  environmental  factors.4
Over  recent  years  the  effects  of  endocrine  peptides,
including  gastrin-releasing  peptide  (GRP),  on  the  central
nervous  system  (CNS)  have  been  investigated.5 GRP  is
released  by  glutamatergic  neurons  and  acts  as  a  neuro-
transmitter  that  regulates  neuronal  excitability.6--8 In  the
brain,  the  gastrin-releasing  peptide  receptor(GRPR)  is  highly
expressed  in  cerebral  regions  related  to  cognitive  function
and  emotional  processing,  such  as  the  dorsal  hippocam-
pus  and  basolateral  amygdala.6--9 Experimental  studies  have
shown  that  pharmacological  blockade  of  GRPR  in  neona-
tal  rats  leads  to  reduced  preference  for  maternal  odor  and
the  development  of  late  and  permanent  deﬁcits  in  social
c
u
snteraction,  a  behavior  consistent  with  animal  models  of
utism.10--12
In  this  experimental  study,  GRP  was  given  intravenously
o  three  children  with  autism  to  test  its  safety,  tolerability,
nd  possible  therapeutic  effects  on  autism  spectrum  disor-
er  (ASD)  symptoms.  To  the  best  of  the  authors’  knowledge,
his  is  the  ﬁrst  report  of  GRP  use  in  humans  with  autism.
ethods
hildren  with  autism  diagnosed  according  to  Diagnostic  and
tatistical  Manual  of  Mental  Disorders,  Fourth  Edition,  Text
evision  (DSM-IV-TR),13 aged  from  3  to  18  years,  were  consid-
red  suitable  for  selection.  Exclusion  criteria  were  serious
linical  disorders,  psychiatric  diseases,  increased  acid  pro-
uction  in  gastrointestinal  system,  secondary  autism,  and
hanges  in  medication  or  other  treatments  during  the  pre-
ious  four  weeks.  Parents  signed  an  informed  consent  and
ommitted  themselves  to  maintaining  the  current  treatment
nchanged  during  the  study  period.
The  sample  was  selected  by  convenience  from  children
een  at  the  ASD  Clinic  at  the  Hospital  de  Clínicas  de  Porto
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legre  (HCPA),  Brazil.  The  ﬁrst  three  children  who  met  the
bove  mentioned  criteria  were  selected.
GRP  was  administered  at  a  160  pmol/kg  dosage  by  con-
inuous  intravenous  infusion  over  30  min.  Patients  were
bserved  for  1 h  after  infusion.  Vital  signs  were  moni-
ored  (arterial  blood  pressure  and  heart  rate)  every  15  min.
dverse  effects  were  monitored.  Afterwards,  the  patient’s
amily  was  encouraged  to  return  normal  daily  routine.  Each
hild  received  infusions  on  four  consecutive  days.
The  results  were  evaluated  throughout  the  Childhood
utism  Rating  Scale  (CARS)  and  Clinical  Global  Impression
CGI)  Scale,  both  administered  on  the  day  before  starting
RP  treatment  and  on  the  last  day  of  infusion.  The  CARS  was
ranslated  and  validated  for  use  in  Brazil  by  Pereira  et  al.  in
008.14
Each  child  underwent  a  second  cycle  of  infusions  after
 two-week  interval,  to  test  for  cause-effect  relationships,
nd  then  followed-up  weekly  for  four  weeks.  The  two-week
nterval  was  chosen  based  on  the  duration  of  objective
mprovements  observed  in  the  ﬁrst  case.
Children  received  oral  omeprazole  during  the  study,  to
revent  any  possible  adverse  effects  from  stimulation  of
cid  production  in  the  gastrointestinal  tract.
The  human  GRP  used  was  synthesized  by  Biopetide  CO
Biotipe  CO.  Inc;  CA,  USA).
The  study  was  approved  by  the  HCPA  Medical  Research
thics  Committee  (project  No.  11-0277).
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ase  1
 is  a  4-year-old  boy.  He  is  an  agitated  child  and  appears  to
ave  unlimited  energy.  He  is  stubborn  and  will  not  accept
eing  told  ‘‘no’’  and  when  he  is  opposed  he  attacks  himself
ith  blows  to  the  head,  but  is  not  aggressive  to  others.  He
refers  to  be  alone  and  does  not  seek  out  social  interac-
ion.  When  people  he  knows  attempt  to  interact,  he  makes
ye  contact  sporadically  and  has  serious  problems  with  joint
ttention.  If  people  he  does  not  know  attempt  to  inter-
ct,  he  is  indifferent.  He  exhibits  stereotypical  movements,
alking  on  tiptoes  and  sporadically  pointing  at  his  nose  with
is  ﬁnger.  His  only  interest  is  toy  cars,  which  he  lines  up,
rranges  by  color,  or  removes  the  wheels  from,  without
ngaging  in  any  type  of  imaginative  play.  He  takes  them  with
im  wherever  he  goes  and  is  not  interested  in  any  other  toys.
e  exhibits  unusual  fear  of  the  hairdryer,  which  sends  him
nto  a  panic.  He  is  only  resistant  to  change  with  relation  to
is  route  to  school.  He  has  rituals  for  going  to  sleep,  and  a
ew  months  before  the  study  outset,  he  acquired  a compul-
ion  for  bathing  and  must  be  washed  ﬁve  or  six  times  each
ay  --  whenever  he  becomes  anxious,  hurts  himself,  or  gets
irty.  He  only  speaks  single-word  sentences  and  a  few  short
hrases.  He  does  not  have  sensory  abnormalities.  He  had
een  attending  school  since  he  was  1  year  and  2  months
ld,  and  has  been  seeing  a  speech  therapist  since  he  was
 years  old.  He  takes  2  mg  risperidone  per  day.  CARS  38.5;
GI:  moderately  ill.
After  the  infusions,  G  lost  his  obsession  with  bathing  and
is  fear  of  the  hairdryer,  stopped  exhibiting  stereotypical
ehavior  with  his  hands  and  reduced  stereotypical  behaviors
r
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ith  his  body,  improved  his  tolerance  of  frustration  and  his
rritability,  and  relaxed  his  pre-sleep  rituals.  He  exhibited
 discrete  improvement  in  the  variety  of  his  interests,  his
lay,  and  the  quality  of  his  social  interaction,  paying  more
oint  attention  and  making  initiatives  at  interaction.  The
ompulsion  for  bathing  and  abnormal  fear  of  the  hairdryer
isappeared  and  the  stereotypical  behaviors  were  attenu-
ted  on  the  ﬁrst  day  of  infusion.  There  was  no  change  to
gitation,  or  verbal  or  non-verbal  communication.  CARS:  34;
GI-S  (severity  scale):  moderately  ill;  CGI-I  (improvement
cale):  much  improved.
The  improvement  in  objective  symptoms  lasted  for  two
eeks.  After  this  period,  the  boy  was  administered  another
ycle  of  infusions,  with  similar  results.  The  compulsion  for
athing  and  stereotypical  movements  with  the  hands  dis-
ppeared  on  the  ﬁrst  day  of  infusions  once  more,  and  the
mprovements  were  maintained  for  two  weeks  after  the  last
nfusion.
G  did  not  exhibit  any  type  of  adverse  effect  after  either
f  the  two  GRP  cycles.
ase  2
O  is  4-year-old  boy.  He  has  verbal  language  and  exhibits
any  echolalias,  both  immediate  and  delayed.  He  is  calm,
ecoming  agitated  only  when  in  situations  that  are  out  of  the
rdinary  or  in  strange  places.  When  opposed,  he  screams  and
s  aggressive  to  himself  and  others  (biting).  He  exhibits  many
tereotypical  behaviors,  such  as  swaying,  ﬂapping,  swinging
is  hands  in  front  of  his  eyes,  walking  on  tiptoes,  or  running
n  short  starts.  He  does  not  play  imaginatively  and  is  not
nterested  in  toys.  He  is  fascinated  by  brands,  logins,  letters,
nd  numbers.  He  does  not  become  ﬁxated  on  routines,  rit-
als,  or  manias.  He  has  poor  social  interaction,  completely
gnoring  his  peers.  He  makes  eye  contact  with  adults  for
hort  periods  and  sometimes  seeks  them  out.  He  has  lit-
le  emotional  response  and  often  laughs  without  reason.  His
arents  report  that  he  has  little  reaction  to  pain  and  spo-
adically  places  objects  in  his  mouth  or  smells  them.  LO  has
egular  speech  therapy,  psychological  and  psychopedagogi-
al  care,  plus  occupational  therapy  and  horse  riding  therapy.
e  was  taking  1.5  mg/day  of  risperidone  and  625  mg/day  of
odium  valproate.  CARS:  42;  CGI-S:  moderately  ill.
After  GRP  infusions,  LO  exhibited  discrete  improvements
n  the  quality  of  his  verbal  communication.  He  became  more
alkative,  making  a  greater  number  of  comments  and  pro-
ucing  unrehearsed  utterances.  He  became  more  tolerant
f  frustration  and  more  sensitive  to  pain.  Social  interaction
nd  stereotypical  behavior  were  unaltered.  CARS  40.5;  CGI-
:  moderately  ill;  CGI-I:  minimally  improved.  LO’s  parents
ere  unable  to  determine  the  effect’s  duration.  After  two
eeks  he  was  given  another  cycle  of  infusions  and  the  results
asted  until  the  end  of  follow-up.  He  did  not  exhibit  any
dverse  effects  from  GRP.
ase  3
 is  boy  aged  4  years  and  3  months.  His  interpersonal
elationships  are  highly  compromised;  he  seeks  isolation
nd  will  only  interact  with  members  of  his  family  after
ersistent  and  vigorous  attempts.  His  emotional  response  is
ighly  compromised  and  he  displays  indifference  and  laughs
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without  reason.  He  walks  on  tiptoes,  performs  little  jumps,
and  exhibits  ﬂapping  and  other  stereotypical  behaviors
with  his  hands.  He  is  uninterested  in  toys,  does  not  play
imaginatively,  and  does  not  play  with  children  his  own  age.
He  is  an  agitated  boy,  he  often  places  objects  in  his  mouth,
and  he  appears  not  to  feel  pain.  He  is  fascinated  by  the
opening  titles  of  soap  operas  and  previews  of  the  news  on
television.  He  says  few  words,  is  not  aggressive,  and  does
not  exhibit  manias,  rituals,  or  ﬁxation  with  routines.  He
receives  regular  psychological  and  psychopedagogical  care,
as  well  as  speech  therapy  and  occupational  therapy.  He  is
not  on  medication.  CARS:  41;  CGI:  moderately  ill.
After  the  infusions,  L  exhibited  an  attenuation  of  stereo-
typical  behaviors  with  the  hands  and  laughter  without
reason.  His  social  interaction  improved,  with  more  social
smiling,  greater  acceptance  of  interactions  initiated  by
peers,  better  joint  attention,  and  better  eye  contact.  He
became  more  affectionate,  allowing  more  physical  contact.
His  play  became  more  creative,  taking  in  a  wider  variety  of
interests.  He  became  more  tolerant  of  frustration  and  more
sensitive  to  pain.  He  became  more  talkative  and  uttered
some  new  words.  CARS:  38;  CGI-S:  moderately  ill,  CGI-I:  min-
imally  improved.  His  parents  were  unable  to  determine  the
duration  of  the  effect.  After  two  weeks,  L  was  given  another
cycle  of  infusions  and  the  results  persisted  until  the  end  of
follow-up.  The  patient  did  not  exhibit  any  adverse  effects.
Fig.  1  illustrates  which  ASD  symptoms  improved  after  the
GRP  infusions,  by  patient.
Discussion
Over  recent  decades,  there  has  been  an  explosive  growth
in  the  number  of  studies  and  publications  on  the  subject  of
ASD.15 Despite  this  volume  of  work,  to  date  no  biological
marker  nor  any  treatments  capable  of  curing  ASD  have  been
identiﬁed.  The  available  drug  treatment  only  acts  on  sec-
ondary  maladaptive  symptoms.  The  majority  are  prescribed
off  label,  since  only  risperidone  and  aripiprazole  have  been
approved  by  the  Food  and  Drug  Administration  (FDA)  for
treatment  of  aggression,  irritability,  and  screaming  ﬁts  in
patients  with  autism.16--18
Evidence  has  suggested  a  link  between  GRP  and  neuropsy-
chiatric  disturbances,  but  the  association  with  autism  has
received  little  attention  in  the  literature  so  far.  Genetic
studies  in  humans  have  suggested  a  possible  link  between
GRPR  and  regulation  of  social  behavior  and  bonding.  An
X;8  translocation  on  the  ﬁrst  intron  of  the  GRPR  gene  has
been  identiﬁed  in  women  with  multiple  osteochondroma  and
autism  being  treated  for  mental  retardation  and  epilepsy,
indicating  that  the  GRPR  gene  is  one  of  the  candidate
genes  for  autism.19 Recent  preclinical  studies  have  raised
the  hypothesis  that  some  ASD  symptoms,  such  as  social
interaction  deﬁcits  and  reduced  interest  in  bonding,  may
be  caused  by  a  lack  of  GRP  action  at  some  early  point  in
development.10,12
GRP  has  previously  been  administered  intravenously
in  humans  to  test  its  effects  on  nutritional  intake  and
vascular  dilation.  In  one  study  it  induced  transitory  vasodila-
tor  effects,  with  pressures  returning  to  normal  in  around
20  min.20 In  another  test,  GRP  was  administered  at  doses  of
10,  40,  or  160  pmol/kg  per  hour  to  healthy  male  volunteers
t
s
eigure  1  Symptoms  of  autism  disorder  spectrum  before  and
fter  intravenous  infusion  of  gastrin-releasing  peptide  (GRP).
n  order  to  evaluate  its  effect  on  eating  behavior  and  satiety;
he  results  showed  a  signiﬁcant  reduction  in  calorie  intake
nd  a  reduction  of  approximately  19%  in  food  intake.21 The
60  pmol/kg  dose  used  in  the  present  case  series  is  larger
han  in  any  of  these  studies.
The  few  previous  studies  of  GRP  in  humans  have  shown
hat  it  is  safe,  which  was  also  conﬁrmed  in  the  present  study,
ince  none  of  the  patients  exhibited  any  adverse  effects.20,21
The  results  of  this  case  series  suggest  that  GRP  may  be
apable  of  improving  key  childhood  autism  symptoms,  for
hich  there  is  not  currently  any  speciﬁc  drug  treatment,
specially  for  stereotypes.
In  the  present  study,  two  of  the  three  patients  exhibited
mprovements  in  social  interaction,  with  discreet  changes  in
oint  attention  and  interaction  initiatives.  The  same  patients
lso  exhibited  a  reduction  in  stereotypical  behavior,  and
ncreased  variety  of  interests  and  improved  quality  of  play,
hich  until  then  had  been  entirely  stereotyped.
Two  cases  exhibited  improvements  in  verbal  language,
ith  more  spontaneous  speech  and  use  of  new  words,
ecame  more  sensitive  to  pain  and  more  tolerant  to  frus-
ration,  and  exhibited  fewer  extreme  responses  such  as
creaming  ﬁts  and  aggression  to  self  and  others.
Although  these  improvements  were  discreet  and  were
valuated  subjectively,  in  one  case  there  was  immediate
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vasodilator in humans. Clin Pharmacol Ther. 2001;69:252--9.06  
mprovement  in  a  compulsion  for  bathing,  which  is  an  objec-
ive  variable  that  is  easy  to  measure  and  which  had  a  clear
ause-effect  relationship,  demonstrated  when  the  effect
as  repeated  after  the  second  cycle  of  GRP.
The  symptoms  that  appeared  to  have  improved  after  GRP
nfusions  varied  across  the  three  cases,  which  may  be  expli-
able  by  the  great  variety  of  symptoms  observed  in  each
atient  prior  to  the  infusions,  which  is  of  course  the  reason
or  the  term  ‘‘autism  spectrum.’’  While  the  improvements
ere  discreet,  it  important  to  point  out  that  this  is  a  pio-
eering  study  in  which  patients  were  given  GRP  for  just  four
ays  at  a  time.  To  date  there  are  no  published  studies  that
ave  investigated  the  safety  of  long-term  administration  of
RP  to  humans.
Although  all  three  families’  responses  indicate  an
mprovement  in  the  CGI  scores,  there  was  a  very  small  reduc-
ion  in  CARS  scores,  which  suggests  that  the  scale  may  not
ave  been  sensitive  enough  to  detect  changes  observed  in
he  study.
In  this  study,  GRP  proved  safe  over  the  short-  and
edium-term,  in  common  with  published  data.
It  is  important  to  point  out  that  since  this  is  a  report  on
 case  series,  this  study  has  inherent  methodological  limita-
ions  and  the  results  should  be  interpreted  with  caution.  The
umber  of  cases  was  small,  there  were  no  controls  or  blind-
ng,  and  the  results  were  assessed  on  the  basis  of  parents’
ubjective  impressions,  with  no  way  to  test  for  the  placebo
ffect.
This  study  has  suggested  that  GRP  may  have  an  effect
n  key  symptoms  of  childhood  autism,  particularly  compul-
ions  and  stereotypies.  Further  studies  are  needed  to  better
valuate  these  results,  with  larger  numbers  of  patients  and
reater  methodological  rigor,  since  administration  of  GRP  to
hildren  with  autism  proved  promising.
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